Skip to search boxSkip to navigationSkip to main content

Molecular imaging with optical coherence tomography using ligand-conjugated microparticles that detect activated endothelial cells: Rational design through target quantification

  • Andrew Jefferson
    ,
  • Rohan S. Wijesurendra
    ,
  • Martina A. McAteer
    ,
  • Janet E. Digby
    ,
  • Gillian Douglas
    ,
  • Thomas Bannister
*Corresponding author for this work
  • University of Oxford
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Objectives: Optical coherence tomography (OCT) is a high resolution imaging technique used to assess superficial atherosclerotic plaque morphology. Utility of OCT may be enhanced by contrast agents targeting molecular mediators of inflammation. Methods and results: Microparticles of iron oxide (MPIO; 1 and 4.5μm diameter) in suspension were visualized and accurately quantified using a clinical optical coherence tomography system. Bound to PECAM-1 on a plane of cultured endothelial cells under static conditions, 1μm MPIO were also readily detected by OCT. To design a molecular contrast probe that would bind activated endothelium under conditions of shear stress, we quantified the expression (basal vs. TNF-activated; moleculesμm -2) of VCAM-1 (not detected vs. 16±1); PECAM-1 (132±6 vs. 198±10) and E-selectin (not detected vs. 46±0.6) using quantitative flow cytometry. We then compared the retention of antibody-conjugated MPIO targeting each of these molecules plus a combined VCAM-1 and E-selectin (E+V) probe across a range of physiologically relevant shear stresses. E+V MPIO were consistently retained with highest efficiency (P<0.001) and at a density that provided conspicuous contrast effects on OCT pullback. Conclusion: Microparticles of iron oxide were detectable using a clinical OCT system. Assessment of binding under flow conditions recommended an approach that targeted both E-selectin and VCAM-1. Bound to HUVEC under conditions of flow, targeted 1 μm E + V MPIO were readily identified on OCT pullback. Molecular imaging with OCT may be feasible in vivo using antibody targeted MPIO.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 579-587 (9 pages)

Journal (Volume, Issue Number)

Atherosclerosis (Volume 219, Issue 2)

Publication milestones

  • Published - 12/2011

Publication status

Published - 12/2011

ISSN

0021-9150

Publication IDs

  • Scopus: 82955187515
  • PubMed: 21872249

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
1.45
SciVal
Author count
10
SciVal
citations
35
SciVal
Paper percentile
87
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
40
Captures
55

Funding Details

This research is supported by the British Heart Foundation . RPC is a Wellcome Trust Senior Research Fellow in Clinical Science. The study was supported by the Oxford Comprehensive Biomedical Research Centre , NIHR funding scheme. RPC and ZB acknowledge the support of the BHF Centre of Research Excellence, Oxford ( RE/08/004 ). FP-B is supported by a Cancer Research UK Programme Grant ( C28461 ; PI: Dr. N. R. Sibson). Flow Cytometry experiments were performed in the Oxford BRC Translational Immunology Laboratory. The BRC Immunology SRL is supported by the NIHR BRC. Phil Townsend is gratefully acknowledged for his general laboratory management.
FundersFunding numbers
NIHR
-
BHF
-
Oxford Comprehensive Biomedical Research Centre
-
Programme Grant
-
BRC
-
CRE
RE/08/004
CRUK
C28461
MRC
G0701128
NHLBI
R01HL104126